CBS 2019
CBSMD教育中心
English

科学研究

科研文章

荐读文献

Dual-antiplatelet treatment beyond 1 year after drug-eluting stent implantation (ARCTIC-Interruption): a randomised trial Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Impact of Lesion Preparation Strategies on Outcomes of Left Main PCI: The EXCEL Trial A volumetric intravascular ultrasound comparison of early drug-eluting stent thrombosis versus restenosis Economic and Quality-of-Life Outcomes of Natriuretic Peptide–Guided Therapy for Heart Failure Optimal duration of dual antiplatelet therapy after drug-eluting stent implantation: a randomized, controlled trial. Sex differences in left main coronary artery stenting: Different characteristics but similar outcomes for women compared with men The Year in Cardiovascular Medicine 2020: Valvular Heart Disease: Discussing the Year in Cardiovascular Medicine for 2020 in the field of valvular heart disease is Professor Helmut Baumgartner and Dr Javier Bermejo. Mark Nicholls reports Prognostic implications of baseline 6‐min walk test performance in intermediate risk patients undergoing transcatheter aortic valve replacement Cardiac and Kidney Benefits of Empagliflozin in Heart Failure Across the Spectrum of Kidney Function: Insights From EMPEROR-Reduced

Original Research2017 Dec 5. [Epub ahead of print]

JOURNAL:Catheter Cardiovasc Interv. Article Link

Rotational atherectomy and new-generation drug-eluting stent implantation

Hachinohe D, Kashima Y, Kanno D et al. Keywords: newer-generation drug-eluting stents; percutaneous coronary intervention; rotational atherectomy

ABSTRACT


OBJECTIVES - The aim of this study was to evaluate the clinical outcomes of rotational atherectomy (RA) followed by new-generation drug-eluting stent (DES) implantation in patients with an extensive amount of calcified and fibrotic plaque.


BACKGROUND - RA followed by new-generation DES implantation for complex lesions has not been thoroughly evaluated.


METHODS - A total of 744 consecutive patients (770 lesions) treated with new-generation DES implantation following RA for de novo lesions between January 2013 and November 2015 were retrospectively identified using our institutional database. Clinical outcomes at 12 months were evaluated and the independent predictors of all-cause death and target vessel failure (TVF) were assessed using Cox regression models.


RESULTS - Target lesion revascularization occurred in 22 lesions (2.9%) and TVF occurred in 51 lesions (6.6%). In a multivariate analysis, hemodialysis, non-ST-segment elevation acute coronary syndrome, low ejection fraction, and HbA1c ≧ 7% were associated with 12-month mortality. Hemodialysis and right coronary artery were identified as independent predictors of TVF (hazard ratio (HR) 4.107, 95% confidence interval (CI) 2.194-7.685, P < .001; HR 2.491, 95% CI 1.023-6.062, P = .044, respectively).


CONCLUSIONS - A good debulking with RA followed by new-generation DES implantation is recommended for patients with an excessive amount of calcified and fibrotic plaque, as this will likely improve the clinical outcomes.


© 2017 Wiley Periodicals, Inc.